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Edited by Lukas HuberAbstract The adipokine resistin is known to induce insulin
resistance in rodent tissues. Increases in adipose tissue mass
are known to have a negative eﬀect on pancreatic beta-cell func-
tion, although the mechanisms are poorly understood. This study
investigated the eﬀects of resistin on insulin secretion, insulin
receptor expression and cell viability in pancreatic beta-cells.
BTC-6 or BRIN-BD11 cells were treated for 24 h with resistin,
and insulin receptor expression, insulin secretion and cell viabil-
ity were measured. Incubation with 40 ng/ml resistin caused sig-
niﬁcant decreases in insulin receptor mRNA and protein
expression, but did not aﬀect insulin secretion. At low concentra-
tions, resistin caused signiﬁcant increases in cell viability. These
data implicate resistin as a factor that may regulate beta-cell
function/viability, and suggests a potential mechanism by which
increased adiposity causes beta-cell dysfunction.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cell viability1. Introduction
It is well recognised that together with reduced insulin sensi-
tivity, impaired pancreatic islet beta-cell function is one of the
two key components in the pathogenesis of type 2 diabetes
(T2D), a condition which is expected to aﬀect over 300 million
people worldwide by 2025 [1]. The precise mechanisms by
which this loss of islet beta-cell function occurs are however
poorly understood. One factor often overlooked is the role
of insulin receptor in the beta-cell, as not only are insulin
receptors expressed in the beta-cell [2], they have been shown
to play a role in regulating beta-cell function, including insulin
secretion [3] and beta-cell mass [4].
Although T2D has a multi-factorial aetiology, one very well-
established risk factor for T2D is obesity [5], with over 90% of
suﬀerers of T2D in Western societies being obese. Until re-
cently adipose tissue was thought to act primarily as an energy
reservoir, allowing the body to negotiate times of famine by
storing triacylglycerol in times of excess, and mobilising it in
times of shortage. A large volume of recent research has how-
ever identiﬁed adipose tissue as a metabolically active endo-*Corresponding author. Fax: +44 1902322714.
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doi:10.1016/j.febslet.2007.06.031crine organ that is able to secrete a signiﬁcant number of
bioactive peptides that have been termed ‘adipokines’. These
molecules include hormones, growth factors and cytokines
such as leptin, resistin, visfatin, adiponectin and TNF-a [6].
It has also been shown that these secretory molecules regulate
a wide variety of cellular functions relevant to both the patho-
genesis and complications of diabetes.
Resistin, a 12.5 kDa cysteine rich adipokine, has been iden-
tiﬁed as a potential link between obesity and diabetes [7,8]. Ini-
tial research showed that resistin induced insulin resistance in
mice when injected into normal mice, and that treating diet-in-
duced diabetic mice with anti-resistin antibody reduced blood
glucose and improved insulin action [5]. Although this initial
ﬁnding has been repeated in rodents, the ability of resistin to
induce insulin resistance in human tissue is much more contro-
versial [9,10]. Resistin expression in adipocytes has also been
shown to be regulated by a wide range of factors including
insulin [11], tumour necrosis factor-alpha [12], metformin
[13] and oestrogen [14].
Interestingly, recent evidence has demonstrated that resistin
is not expressed exclusively in adipose tissue, with at least one
group demonstrating its expression in islet tissue and clonal
beta-cells [15]. Resistin expression has also been identiﬁed in
the liver [16] and it has been suggested that it is rather in liver
disease that resistin may induce insulin resistance in humans
[17]. In lean subjects, the serum levels of resistin have been re-
ported to be approximately 5–15 ng/ml [18,19], whereas in
either T2D or obesity, the serum level increases to as high as
40 ng/ml [20]. These observations reinforce the theory that in
the obese and/or diabetic condition, islet tissues are exposed
to higher than normal concentrations of resistin.
The expression of resistin in islet tissue could possibly sug-
gest an islet or beta-cell speciﬁc role for resistin, however there
is little published research into any potential role for resistin in
regulating beta-cell function. This study therefore aimed to
investigate the eﬀect that pathological concentrations of resi-
stin had on pancreatic beta-cell function, viability and insulin
receptor gene expression.2. Materials and methods
2.1. Cell culture and treatment
All materials were purchased from Sigma (Poole, UK) unless other-
wise stated.
bTC-6 cells were purchased from the ATCC collection (LGC Pro-
mochem, UK), BRIN-BD11 cells were a gift from Prof. Peter Flatt
(University of Ulster, Coleraine, Northern Ireland, UK). Cells fromblished by Elsevier B.V. All rights reserved.
Fig. 1. Resistin decreases insulin receptor mRNA expression. Incuba-
tion with 40 ng/ml resistin for 24 h caused a signiﬁcant 70% decrease in
the levels of insulin receptor mRNA compared to control as detected
by real-time PCR (P = 0.0005). n = 4.
Fig. 2. Resistin decreases insulin receptor protein expression. Twenty-
four-hours incubation with 40 ng/ml resistin also caused a marked
decrease in the levels of insulin receptor protein compared to control,
with a decrease in detected band intensity of 60% being recorded.
Mouse skeletal muscle cell lysate (SM) was used as a positive control
(n = 3 for each treatment).
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11 mmol/l glucose RPMI-1640 (supplemented with 2 mmol/l L-gluta-
mine, 50 IU/ml penicillin and 50 lg/ml streptomycin, 10% foetal bo-
vine serum) in a 5% CO2 incubator at 37 C incubator. All
treatments were performed in supplemented but serum-free RPMI-
1640.
For experimental treatments, cells were seeded into T75 ﬂasks (bTC-
6 cells for mRNA and protein expression), 1.5 · 105 cells per well in a
24 well plate (BRIN-BD11 cells for insulin secretion) or 0.5 · 104 in 96-
well plates (bTC-6 cells for modiﬁed MTS cell viability assay). Cells
were allowed to attach for 24 h and subsequently were incubated with
recombinant rat resistin (Cambridge Biosciences, Cambridge, UK) for
24 h. For insulin receptor expression and insulin secretion assays a
concentration of 40 ng/ml resistin was used, for cell viability a range
of 0–40 ng/ml was used.
2.2. Measurement of insulin receptor mRNA and protein expression
For mRNA expression experiments, total RNA was extracted using
an SV Total RNA Isolation kit (Promega, Southampton, UK) and was
quantiﬁed and assessed using gel electrophoresis. One microgram of
total RNA was reverse transcribed using AMV reverse transcriptase
(Promega, Southampton, UK) and oligo dT15 primers (Bioline, UK).
For real-time PCR, resulting cDNA’s were diluted 1 in 2 and subse-
quently ampliﬁed for 40 cycles in an iCycler (Biorad, Hemel Hemp-
stead, UK) using a proprietary SYBR Green Fluorescein Mix
(Primerdesign, Southampton, UK) and in house designed sequence
speciﬁc primers for mouse insulin receptor (sense primer
AATGGCAACATCACACACTACC; anti-sense primer CAG-
CCCTTTGAGACA-ATAATCC). For housekeeping genes and resi-
stin expression, pre-validated mouse actin, GAPDH and resistin
primers were purchased (Primerdesign, Southampton, UK). Relative
expression of insulin receptor to housekeeping genes was calculated
by comparison of Ct values (delta  delta Ct). Primer eﬃciencies for
both genes of interest and housekeeping genes were between 95%
and 100% as measured by Linreg software (supplied by Primerdesign,
Southampton, UK).
For protein expression experiments, total cellular protein was ex-
tracted from control/treated cells for 1 h at 4 C in a detergent based
cell lysis buﬀer (20 mmol/l Tris, 150 mmol/l NaCl, 1 mmol/l EDTA,
1% Triton X, protease inhibitor cocktail) before being quantiﬁed using
DC protein assay kit (Biorad, Hemel Hempstead, UK). Cell lysates
were then centrifuged at 13000 G for 10 min to separate out protein
and boiled. 40 lg total protein was loaded per sample and run through
a 4–8% polyacrylamide gel. Samples were subsequently transferred to a
nitrocellulose membrane (Geneﬂow, Lichﬁeld, UK), blocked using 5%
non-fat milk and probed using rabbit polyclonal anti-insulin receptor
(Autogen Bioclear, UK) at 1:300 at 4 C overnight and rabbit anti-
goat IgG-conjugated secondary antibody (Autogen Bioclear, UK) at
1:2000 at room temperature for 1 h. After a series of washes in TBS-
T, membranes were developed using ECL+ detection kit (Amersham,
Little Chalfont, UK) and images were visualised using a Storm Phos-
phorimager (Amersham, Little Chalfont, UK). Band density was mea-
sured using Scion image software (NIH). To ensure equal band
loading, samples were also probed for beta-actin protein expression
using a polyclonal rabbit anti-beta actin antibody at 1:500 dilution
(Autogen Bioclear, UK).
2.3. Cell viability
For measurement of cell viability, cells were plated out at a density
of 2 · 104 cells per well in a 96-well plate and were treated as described
above for 24 h. After this period, CellTiter 96 Aqueous One Solution
Cell Proliferation Assay solution (Promega, Southampton, UK) was
added for 2 h. Absorbance at 490 nm was measured and recorded.
2.4. Insulin secretion
For insulin secretion, the reportedly glucose responsive clonal ro-
dent pancreatic beta-cell line BRIN-BD11 was used. BRIN-BD11 cells
between passages 30 and 36 were plated out at a density of 0.2 · 104
cells per well in a 96-well plate and allowed to attach overnight. Cells
were subsequently treated with 0, 20 and 40 ng/ml resistin for 24 h in
serum free RPMI. After this period, cells were immersed in RPMI con-
taining 2.2 mm glucose and then stimulated with 22 mM glucose, the
media from this last treatment being collected and assayed for insulin
content using a proprietary Rat insulin ELISA (Mercodia, Sweden).2.5. Statistical analysis
Statistical analysis of all data obtained was undertaken using the
SPSS v.10 statistical analysis package. For all analysis, normal distri-
bution was assumed due to analysis of similar previous experimenta-
tion using these cells. For single comparisons (control vs treatment)
a two tailed unpaired t-test was employed; where multiple comparisons
were required ANOVA with Tukey’s post-hoc test was applied.
P 6 0.05 was taken as the point of signiﬁcance. For each set of exper-
iments, where ‘n=’ is stated, ‘n=’ refers to individual experiments, each
run in either quadruplicate or quintuplicate. All graphs are displayed
as means ± S.E.M. * denotes P < 0.05.3. Results
3.1. Resistin reduces insulin receptor mRNA expression
Qualitative real-time SYBR Green evaluation of insulin
receptor mRNA expression showed that when bTC-6 cells
were incubated with 40 ng/ml resistin for 24 h, a signiﬁcant de-
crease of 70% (Fig. 1) compared to control was seen
(P = 0.0005).
3.2. Resistin reduces insulin receptor protein expression
Twenty-four-hours incubation with 40 ng/ml resistin also
caused a marked reduction in the level of insulin receptor pro-
tein expression detectable by Western blot. Resistin treated
samples gave a detected band intensity of approximately 60%
less than control samples (Fig. 2).
3.3. Resistin increases cell viability at physiological, but not
pathological concentrations
Twenty-four-hours incubation with resistin caused signiﬁ-
cant increases in cell viability as assessed by modiﬁed MTS as-
say compared to control when bTC-6 cells were incubated at
Fig. 3. Resistin increases bTC-6 cell viability at normal but not
elevated levels. Incubation with concentrations from 5 to 20 ng/ml
resistin caused signiﬁcant increases of as much as 45% in cell viability
compared to control (P < 0.01). However, when the concentration of
resistin was increased to 30–40 ng/ml these increases in cell viability
were not seen (n = 5 for each treatment).
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but at higher ‘pathological’ concentrations associated with
obesity and diabetes (30–40 ng/ml), these increases in cell via-
bility were not seen (Fig. 3), resulting in a bell-shaped response
curve. Similar results were seen using BRIN-BD11 cells.
3.4. Resistin mRNA is expressed in bTC-6 and BRIN-BD11
cells
Using both standard and real-time PCR to evaluate resistin
mRNA expression in bTC-6 and BRIN-BD11 cells, resistin
mRNA was detected in both cell lines (data not shown). Using
real-time PCR the cycle threshold (Ct) seen in these cells was
between 23 and 26, suggesting a relatively high level of expres-
sion.4. Resistin has no eﬀect on insulin secretion from BRIN-BD11
cells
Static incubation for 24 h with 40 ng/ml resistin had no eﬀect
on high glucose (22 mmol/l) stimulated insulin secretion over
1 h from the reportedly glucose responsive BRIN-BD11 cell
line (Fig. 4).Fig. 4. Resistin has no eﬀect on insulin secretion from BRIN-BD11
cells. Incubation with either 20 ng/ml or 40 ng/ml resistin for 24 h had
no signiﬁcant eﬀect on subsequent 1 h GSIS (stimulated at 22 mM
glucose) compared to control cells (n = 4 for each treatment).5. Discussion
The potential role of resistin as a link between obesity and
T2D in humans is controversial. This investigation however
provides evidence that high concentrations of resistin could
possibly lead to negative eﬀects in pancreatic beta-cells, via a
down-regulation of expression of the insulin receptor. We
show here that when beta-cells are exposed to the kind of ele-
vated levels of resistin which might be seen in obesity/T2D, a
signiﬁcant reduction in the level of insulin receptor mRNA
and protein is seen, with decreases of 70% and 60%, respec-
tively being seen. This observation is a novel one, as not only
is there a dearth of published data involving resistin regulation
of gene expression in the beta-cell, but there is also a lack of
published material dealing with any eﬀects that resistin might
have on insulin receptor expression in non-islet tissue, even
though data suggesting that resistin has a role in insulin resis-
tance in rodents [8].
The observation that resistin can reduce insulin receptor
expression in the beta-cell has profound importance. Research
has shown that when the insulin receptor is knocked out in a
beta-cell speciﬁc manner, hyperglycaemia results due to a loss
of both beta-cell mass and secretory function [21], suggesting a
central role for autocrine actions of insulin in maintaining pan-
creatic function. This ﬁnding suggests that if the eﬀect that we
report here occurs in vivo, then resistin may provide a link be-
tween increased adiposity and dysregulation of pancreatic
beta-cell function and mass. Interestingly, the current study
also found that incubation with this high concentration of res-
istin did not cause any signiﬁcant change in the ability of the
beta-cell to secrete insulin in response to high glucose chal-
lenge. This is in contrast to a recent study which found that
at elevated glucose concentrations resistin caused a decrease
in GSIS in isolated islet tissue (although this study used a
much lower glucose concentration than was used here, and is-
let tissue is well established as being more ‘glucose-responsive’
than clonal beta-cell lines) [23]. Both these studies used 24-h
incubations to test resistin’s eﬀects on GSIS. Whether or not
longer-term exposure to elevated resistin levels directly regu-
lates insulin secretion is a matter for future study, and might
provide valuable information regarding the role of resistin in
regulation of insulin secretion.
The novel observation that resistin regulates beta-cell viabil-
ity is a particularly interesting one. Fig. 3 shows that at lower
concentrations of resistin (similar to those reported in normal
lean subjects) beta-cell viability was signiﬁcantly increased by
50% compared to control cells. However, when the concentra-
tion of resistin was increased to levels which might be seen in
obesity or T2D (30–40 ng/ml), this eﬀect was reversed and
there was no detectable change in cell viability compared to
control cells. These data suggest the possibility that at the low-
er and more ‘physiological’ levels, resistin may act as a beta-
cell growth factor (or possibly might combine this with an
anti-apoptotic eﬀect), potentially as part of an adipo-insular
axis whose role it is to maintain beta-cell mass under ‘adipo-
toxic’ challenge. However at the much higher, and more ‘path-
ological’ resistin concentrations this proliferative eﬀect does
not occur, potentially suggesting that any axis of this type
might become defective in the presence of elevated serum res-
istin concentrations. We have also observed in our lab that
other adipokines can elicit a similar proliferative eﬀect on clo-
nal beta-cells and when this is taken into account with the well
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(reviewed in [22]) it becomes clear that this might be a possible
mechanism by which increased adiposity negatively regulates
beta-cell mass as well as beta-cell function.
It is also very interesting that resistin is expressed in the beta-
cell, and at relatively high levels. The presence of resistin
mRNA has previously been reported in human islets [15],
and our results suggest that this expression occurs speciﬁcally
in the beta-cell as well as in the whole islet. Expression levels
were found to be high, with Ct values of between 23 and 26
being seen. Quite what the role of resistin in the beta-cell might
be remains poorly understood, and is an area which could pro-
vide valuable information regarding the actions of this adipo-
kine in the pathogenesis of T2D, although the possibility exists
that it could act as a mediator.
The observations reported here are of particular importance
in light of a recently published study, which showed that resi-
stin has the ability to induce insulin resistance in pancreatic is-
lets [23]. It is entirely possible that this reported induction of
pancreatic islet insulin resistance by resistin is related to the de-
crease in insulin receptor expression that we report here; fur-
ther studies will be required to conﬁrm this. In conclusion
our results suggest a central role for resistin in modulating
beta-cell function in obesity and T2D, and therefore might al-
low future research to exploit this as a therapeutic avenue.
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